PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), confirms the filing to EMA for the Marketing Authorization Application for masitinib in the treatment of pancreatic cancer.
